Ireland Cancer Center - Developmental Therapeutics Review - Q4 2010

Global Markets Direct, December 2010, Pages: 59

Ireland Cancer Center – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Ireland Cancer Center – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Ireland Cancer Center.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ireland Cancer Center with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of Ireland Cancer Center’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in Ireland Cancer Center’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate Ireland Cancer Center’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of Ireland Cancer Center in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with Ireland Cancer Center.
- Avoid Intellectual Property Rights related issues.

List of Tables
List of Figures
Ireland Cancer Center Snapshot
Ireland Cancer Center Overview
Key Information
Key Facts
Ireland Cancer Center – Research and Development Overview
Key Therapeutic Areas
Ireland Cancer Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ireland Cancer Center – Pipeline Products Glance
Ireland Cancer Center – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ireland Cancer Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ireland Cancer Center – Drug Profiles
Alimta + Gemzar
Product Description
Mechanism of Action
R&D Progress
Etoposide + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Topotecan
Product Description
Mechanism of Action
R&D Progress
Alimta + Gemzar
Product Description
Mechanism of Action
R&D Progress
Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine + Rituximab + Sargramostim
Product Description
Mechanism of Action
R&D Progress
Brostallicin
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Paclitaxel + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
cisplatin + etoposide
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Topotecan hydrochloride
Product Description
Mechanism of Action
R&D Progress
Docetaxel
Product Description
Mechanism of Action
R&D Progress
filgrastim + cisplatin + etoposide + paclitaxel + topotecan hydrochloride
Product Description
Mechanism of Action
R&D Progress
filgrastim + cisplatin + etoposide + paclitaxel + topotecan hydrochloride
Product Description
Mechanism of Action
R&D Progress
Letrozole + CCI-779
Product Description
Mechanism of Action
R&D Progress
Letrozole + Tipifarnib
Product Description
Mechanism of Action
R&D Progress
monoclonal antibody CAL + zoledronic acid
Product Description
Mechanism of Action
R&D Progress
monoclonal antibody CAL + zoledronic acid
Product Description
Mechanism of Action
R&D Progress
pegylated liposomal doxorubicin hydrochloride
Product Description
Mechanism of Action
R&D Progress
pemetrexed disodium + gemcitabine
Product Description
Mechanism of Action
R&D Progress
T900607
Product Description
Mechanism of Action
R&D Progress
temozolomide
Product Description
Mechanism of Action
R&D Progress
Topotecan + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
combretastatin A4 phosphate
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide + docetaxel + doxorubicin hydrochloride
Product Description
Mechanism of Action
R&D Progress
Docetaxel + (Doxorubicin + Cyclophosphamide)
Product Description
Mechanism of Action
R&D Progress
docetaxel + doxorubicin + cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
HER-2/neu peptide vaccine
Product Description
Mechanism of Action
R&D Progress
Ireland Cancer Center – Pipeline Analysis
Ireland Cancer Center – Pipeline Products by Therapeutic Class
Ireland Cancer Center Pipeline Products By Target
Ireland Cancer Center – Pipeline Products by Route of Administration
Ireland Cancer Center – Pipeline Products by Molecule Type
Ireland Cancer Center – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• The Irish Defense Industry - Market Opportunities and Entry Strategies, Analyses and Forecasts to 2017
• The Irish Defense Industry: Market Opportunities and Entry Strategies, Analyses and Forecasts to 2016
• Army Expenditure in Ireland to 2017: Market Brief
• Navy Expenditure in Ireland to 2017: Market Brief
• The Irish Defense Industry - Competitive Landscape and Strategic Insights to 2017: Market Profile
• Defense Expenditure in Ireland to 2017: Market Review
• Homeland Security Expenditure in Ireland to 2017: Market Review
• Army Expenditure in Ireland to 2016: Market Brief
• Navy Expenditure in Ireland to 2016: Market Brief
• The Irish Defense Industry - Market Opportunities and Entry Strategies Analyses and Forecasts to 2015